Survivin regulation by HER2 through NF-κB and c-myc in irradiated breast cancer cells

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 7, 2011, Pages 1542-1550

  Papanikolaou, Vassilis ^a,b   Iliopoulos, Dimitrios ^c   Dimou, Ioannis ^d   Dubos, Stephanie ^b   Kappas, Constantine ^a   Kitsiou Tzeli, Sofia ^e   Tsezou, Aspasia ^a,b  

^a UNIVERSITY OF THESSALY   (Greece)

^b Institute for Biomedical Research and Technology   (Greece)

^c HARVARD MEDICAL SCHOOL   (United States)

^d TECHNICAL UNIVERSITY OF CRETE   (Greece)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Breast cancer; C myc; HER2 neu; Irradiation; NF ; Survivin regulation

Indexed keywords

BIRC5 PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; MYC PROTEIN; TRANSCRIPTION FACTOR;

ARTICLE; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PROMOTER REGION; RADIATION EXPOSURE; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NF-KAPPA B; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, ERBB-2; TRANSCRIPTION FACTORS;

EID: 79959406230     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2010.01149.x     Document Type: Article

References (33)

1. Feuer EJ, Wun LM, Boring CC, et al The lifetime risk of developing breast cancer. J Natl Cancer Inst. 1993; 85: 892-7.
2. Cuddihy AR, Bristow RG. The p53 protein family and radiation sensitivity: yes or no Cancer Metastasis Rev. 2004; 23: 237-57.
3. Gudkov AV, Komarova EA. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer. 2003; 3: 117-29.
4. Liu W, Ip MM, Podgorsak MB, et al Disruption of estrogen receptor alpha-p53 interaction in breast tumors: a novel mechanism underlying the anti-tumor effect of radiation therapy. Breast Cancer Res Treat. 2009; 115: 43-50.
5. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997; 3: 917-21.
6. Cosgrave N, Hill AD, Young LS. Growth factor-dependent regulation of survivin by c-myc in human breast cancer. J Mol Endocrinol. 2006; 37: 377-90.
7. Deveraux QL, Leo E, Stennicke HR, et al Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J. 1999; 18: 5242-51.
8. Li QX, Zhao J, Liu JY, et al Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers. Cancer Biol Ther. 2006; 5: 860-6.
9. Tanaka K, Iwamoto S, Gon G, et al Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res. 2000; 6: 127-34.
10. Jin XD, Gong L, Guo CL, et al Survivin expressions in human hepatoma HepG2 cells exposed to ionizing radiation of different LET. Radiat Environ Biophys. 2008; 47: 399-404.
11. Saito T, Hama S, Izumi H, et al Centrosome amplification induced by survivin suppression enhances both chromosome instability and radiosensitivity in glioma cells. Br J Cancer. 2008; 98: 345-55.
12. Sharma H, Sen S, Lo Muzio L, et al Antisense-mediated downregulation of anti-apoptotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy. Cancer Biol Ther. 2005; 4: 720-7.
13. Jiang Y, Saavedra HI, Holloway MP, et al Aberrant regulation of survivin by the RB/E2F family of proteins. J Biol Chem. 2004; 279: 40511-20.
14. Kanda N, Seno H, Konda Y, et al STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene. 2004; 23: 4921-9.
15. Kawakami H, Tomita M, Matsuda T, et al Transcriptional activation of survivin through the NF-kappaB pathway by human T-cell leukemia virus type I tax. Int J Cancer. 2005; 115: 967-74.
16. Ma H, Nguyen C, Lee KS, et al Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene. 2005; 24: 3619-31.
17. Chu JS, Shew JY, Huang CS. Immunohistochemical analysis of survivin expression in primary breast cancers. J Formos Med Assoc. 2004; 103: 925-31.
18. Xia W, Bisi J, Strum J, et al Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers. Cancer Res. 2006; 66: 1640-7.
19. Liang K, Lu Y, Jin W, et al Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther. 2003; 2: 1113-20.
20. Slamon DJ, Godolphin W, Jones LA, et al Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244: 707-12.
21. Satra M, Tsougos I, Papanikolaou V, et al Correlation between radiation-induced telomerase activity and human telomerase reverse transcriptase mRNA expression in HeLa cells. Int J Radiat Biol. 2006; 82: 401-9.
22. Tamm I, Wang Y, Sausville E, et al IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998; 58: 5315-20.
23. Siddiqa A, Long LM, Li L, et al Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways. BMC Cancer. 2008; 8: 129.
24. Papanikolaou V, Iliopoulos D, Dimou I, et al The involvement of HER2 and p53 status in the regulation of telomerase in irradiated breast cancer cells. Int J Oncol. 2009; 35: 1141-9.
25. Kappler M, Bache M, Bartel F, et al Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53. Cancer Gene Ther. 2004; 11: 186-93.
26. Rodel F, Hoffmann J, Distel L, et al Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res. 2005; 65: 4881-7.
27. Mita AC, Mita MM, Nawrocki ST, et al Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008; 14: 5000-5.
28. Johnson RA, Ince TA, Scotto KW. Transcriptional repression by p53 through direct binding to a novel DNA element. J Biol Chem. 2001; 276: 27716-20.
29. Martin DW, Munoz RM, Subler MA, et al p53 binds to the TATA-binding protein-TATA complex. J Biol Chem. 1993; 268: 13062-7.
30. Martinato F, Cesaroni M, Amati B, et al Analysis of Myc-induced histone modifications on target chromatin. PLoS One. 2008; 3: e3650.
31. Asanuma H, Torigoe T, Kamiguchi K, et al Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res. 2005; 65: 11018-25.
32. Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009; 8: 33-40.
33. Sethi G, Ahn KS, Aggarwal BB. Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. Mol Cancer Res. 2008; 6: 1059-70.